Bharat Parenterals マネジメント

マネジメント基準チェック /24

Bharat Parenteralsの CEO はBharatkumar Desaiで、 Sep2014年に任命され、の在任期間は 10.17年です。は、会社の株式の11.37%を直接所有しており、その価値は₹ 1.25B 。経営陣と取締役会の平均在任期間はそれぞれ6.3年と6.8年です。

主要情報

Bharatkumar Desai

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	10.2yrs
CEOの所有権	11.4%
経営陣の平均在職期間	6.3yrs
取締役会の平均在任期間	6.8yrs

経営陣の近況

Recent updates

CEO報酬分析

Bharat Parenterals の収益と比較して、Bharatkumar Desai の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-₹28m
Jun 30 2024	n/a	n/a	₹83m
Mar 31 2024	n/a	n/a	₹145m
Dec 31 2023	n/a	n/a	₹252m
Sep 30 2023	n/a	n/a	₹243m
Jun 30 2023	n/a	n/a	₹228m
Mar 31 2023	₹14m	₹14m	₹157m
Dec 31 2022	n/a	n/a	₹180m
Sep 30 2022	n/a	n/a	₹165m
Jun 30 2022	n/a	n/a	₹145m
Mar 31 2022	₹14m	₹14m	₹213m
Dec 31 2021	n/a	n/a	₹189m
Sep 30 2021	n/a	n/a	₹230m
Jun 30 2021	n/a	n/a	₹215m
Mar 31 2021	₹13m	₹13m	₹204m
Dec 31 2020	n/a	n/a	₹256m
Sep 30 2020	n/a	n/a	₹283m
Jun 30 2020	n/a	n/a	₹260m
Mar 31 2020	₹14m	₹14m	₹241m
Dec 31 2019	n/a	n/a	₹222m
Sep 30 2019	n/a	n/a	₹207m
Jun 30 2019	n/a	n/a	₹208m
Mar 31 2019	₹14m	₹14m	₹212m
Dec 31 2018	n/a	n/a	₹167m
Sep 30 2018	n/a	n/a	₹134m
Jun 30 2018	n/a	n/a	₹117m
Mar 31 2018	₹3m	₹3m	₹91m

報酬と市場: Bharatkumarの総報酬がIndian市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。

報酬と収益: Bharatkumarの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Bharatkumar Desai (60 yo)

10.2yrs

在職期間

₹14,336,875

報酬

Mr. Bharatkumar Rameshchandra Desai serves as Chairman of Bharat Parenterals Limited and serves as its Director since September 30, 1992. He has been with Bharat Parenterals Limited since September 30, 199...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Bharatkumar Desai	Chairman & MD	10.2yrs	₹14.34m	11.37% ₹ 1.2b
Jignesh Shah	Chief Financial Officer	6.3yrs	₹1.03m	データなし
Krutika Bhattbhatt	Company Secretary & Compliance Officer	1.1yrs	データなし	データなし
Nikita Desai	Marketing Manager	no data	データなし	1.29% ₹ 141.5m
Himaben Desai	President of Commercial	no data	₹200.00m	14.75% ₹ 1.6b
Hemang Shah	Executive Director	no data	₹2.59m	データなし

6.3yrs

平均在職期間

経験豊富な経営陣: 541096の経営陣は経験豊富で経験豊富です（平均在職期間は6.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Bharatkumar Desai	Chairman & MD	32.2yrs	₹14.34m	11.37% ₹ 1.2b
Hemang Shah	Executive Director	14.3yrs	₹2.59m	データなし
Shaileshkumar Gabhawala	Independent Non-Executive Director	7.3yrs	₹20.00k	データなし
Zankhana Sheth	Independent Non-Executive Director	6.3yrs	₹20.00k	データなし
Sanjay Shah	Non Executive Director	4.1yrs	₹10.00k	データなし
Mukeshbhai Patel	Non-Executive Independent Director	4.2yrs	₹20.00k	0.0015% ₹ 167.7k

6.8yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: 541096の取締役会は経験豊富であると考えられます ( 6.8年の平均在任期間)。

Bharat Parenterals マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Bharat Parenterals Limited, Annual General Meeting, Jul 02, 2024

Bharat Parenterals Limited, Annual General Meeting, Jul 02, 2024

Insufficient new directors

Bharat Parenterals Limited, Annual General Meeting, Sep 30, 2023

Bharat Parenterals Limited, Annual General Meeting, Sep 30, 2023

Bharat Parenterals Limited, Annual General Meeting, Sep 27, 2022

Recent updates

Second quarter 2025 earnings released: ₹27.00 loss per share (vs ₹6.07 profit in 2Q 2024)

Bharat Parenterals Limited to Report Q2, 2025 Results on Oct 29, 2024

First quarter 2025 earnings released: ₹14.71 loss per share (vs ₹13.03 profit in 1Q 2024)

Bharat Parenterals Limited to Report Q1, 2025 Results on Aug 08, 2024

Bharat Parenterals Limited to Report Q1, 2025 Results on Aug 08, 2024

Bharat Parenterals Limited (BSE:541096) agreed to acquire an unknown majority stake in Varenyam Biolifesciences Private Limited for INR 22.56 million.

Upcoming dividend of ₹1.00 per share

Bharat Parenterals Limited, Annual General Meeting, Jul 02, 2024

Bharat Parenterals Limited, Annual General Meeting, Jul 02, 2024

New minor risk - Shareholder dilution

New minor risk - Market cap size

Full year 2024 earnings released: EPS: ₹24.94 (vs ₹42.14 in FY 2023)

Bharat Parenterals Limited to Report Q4, 2024 Results on May 22, 2024

Bharat Parenterals Limited announced that it expects to receive INR 981.500535 million in funding

Bharat Parenterals Limited announced that it expects to receive INR 981.500535 million in funding

Investor sentiment improves as stock rises 16%

New major risk - Share price stability

Investor sentiment improves as stock rises 15%

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improves as stock rises 19%

Third quarter 2024 earnings released: EPS: ₹6.45 (vs ₹4.94 in 3Q 2023)

Bharat Parenterals Limited to Report Q3, 2023 Results on Feb 13, 2024

Investor sentiment improves as stock rises 24%

Second quarter 2024 earnings released: EPS: ₹6.07 (vs ₹17.19 in 2Q 2023)

Insufficient new directors

Bharat Parenterals Limited Declares Dividend for the Financial Year 2022 to 2023

Bharat Parenterals Limited, Annual General Meeting, Sep 30, 2023

Bharat Parenterals Limited, Annual General Meeting, Sep 30, 2023

Investor sentiment improves as stock rises 34%

New minor risk - Share price stability

First quarter 2024 earnings released: EPS: ₹13.03 (vs ₹2.03 in 1Q 2023)

Bharat Parenterals Limited to Report Q1, 2024 Results on Aug 09, 2023

Bharat Parenterals Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023

Bharat Parenterals Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023

Full year 2023 earnings released: EPS: ₹28.40 (vs ₹36.68 in FY 2022)

Bharat Parenterals Limited to Report Q4, 2023 Results on May 20, 2023

Third quarter 2023 earnings released: EPS: ₹4.94 (vs ₹2.32 in 3Q 2022)

Investor sentiment deteriorated over the past week

Second quarter 2023 earnings released: EPS: ₹17.19 (vs ₹13.88 in 2Q 2022)

Bharat Parenterals Limited, Annual General Meeting, Sep 27, 2022

First quarter 2023 earnings released: EPS: ₹2.03 (vs ₹13.49 in 1Q 2022)

Full year 2022 earnings released: EPS: ₹36.67 (vs ₹35.59 in FY 2021)

Investor sentiment improved over the past week

Bharat Parenterals Limited to Report Q4, 2022 Results on May 28, 2022

Investor sentiment improved over the past week

Now 20% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: EPS ₹13.88 (vs ₹11.26 in 2Q 2021)

Full year 2021 earnings released: EPS ₹35.59 (vs ₹42.14 in FY 2020)

Investor sentiment improved over the past week

Bharat Parenterals Limited Receives the License and Authorization from Drugs Controller General of India and Central Drugs Standard Control Organization, New Delhi

Investor sentiment improved over the past week

New 90-day low: ₹341

Third quarter 2021 earnings released: EPS ₹9.46 (vs ₹14.11 in 3Q 2020)

New 90-day low: ₹345

New 90-day low: ₹365

Bharat Parenterals Limited Approves Appointment of Lubhanshi Jhalani as Company Secretary and Compliance Officer

Bharat Parenterals Limited Announces Resignation of Monica Ahir, Company Secretary

New 90-day high - ₹457

First quarter earnings released

Bharat Parenterals Limited to Report Q1, 2021 Results on Aug 20, 2020

New 90-day high - ₹422

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

マネジメント基準チェック /24